Advertisement

Specialty News

February 13, 2017
February 13, 2017
Marathon Pharmaceuticals will charge $89,000 annually for its Duchenne muscular dystrophy (DMD) drug in the United States. The drug, deflazacort,...
Marathon Pharmaceuticals will charge $89,000 annually for its Duchenne muscular dystrophy (DMD) drug in the United States. The drug, deflazacort, has been available in Europe for years at just a fraction of that cost.
MORE
February 13, 2017
February 13, 2017
Health systems are increasingly turning to pharmacogenomics as a way to enhance therapeutic decision-making. At the 2016 American Heart Association'...
Health systems are increasingly turning to pharmacogenomics as a way to enhance therapeutic decision-making. At the 2016 American Heart Association's Scientific Sessions, Larisa H.
MORE
February 13, 2017
February 13, 2017
Sen. Chuck Grassley (R-IA), chairman of the Senate Judiciary Committee, has opened an inquiry into potential abuses of the Orphan Drug Act that may...
Sen. Chuck Grassley (R-IA), chairman of the Senate Judiciary Committee, has opened an inquiry into potential abuses of the Orphan Drug Act that may have contributed to high prices on commonly used drugs.
MORE
February 10, 2017
February 10, 2017
FDA has approved deflazacort (Emflaza—Marathon Pharmaceuticals) tablets and oral suspension for the treatment of individuals aged 5 years and older...
FDA has approved deflazacort (Emflaza—Marathon Pharmaceuticals) tablets and oral suspension for the treatment of individuals aged 5 years and older with Duchenne muscular dystrophy (DMD). This is the first FDA approval of any corticosteroid to treat DMD and the first approval of deflazacort for any use in the United States.
MORE
February 07, 2017
February 07, 2017
CDC's Advisory Committee on Immunization Practices (ACIP) has finalized the 2017 vaccination schedule for U.S. adults. Among other key changes, the...
CDC's Advisory Committee on Immunization Practices (ACIP) has finalized the 2017 vaccination schedule for U.S. adults. Among other key changes, the panel recommends against use of live attenuated influenza vaccine for the 2016–17 season, due to poor efficacy.
MORE
January 05, 2017
January 05, 2017
A new report by the HHS Inspector General found that federal payments for Medicare Part D catastrophic coverage, which pays 80% of drug costs after...
A new report by the HHS Inspector General found that federal payments for Medicare Part D catastrophic coverage, which pays 80% of drug costs after a beneficiary has spent a certain amount annually, surpassed $33 billion in 2015, more than triple the amount paid in 2010.
MORE
January 05, 2017
January 05, 2017
Genoa, a behavioral health pharmacy and telepsychiatry company, announced Wednesday that it has acquired Advanced Pharmacy Solutions (APS), based in...
Genoa, a behavioral health pharmacy and telepsychiatry company, announced Wednesday that it has acquired Advanced Pharmacy Solutions (APS), based in Mississippi. The acquisition will expand Genoa's footprint throughout Mississippi, Tennessee, Arkansas, and South Carolina, serving an additional 50 clinics.
MORE
October 07, 2016
October 07, 2016
**
MORE
September 26, 2016
September 26, 2016
FDA has said that draft guidance on how an interchangeable biosimilar will be defined should come out by the end of 2016, but the just-released user...
FDA has said that draft guidance on how an interchangeable biosimilar will be defined should come out by the end of 2016, but the just-released user fee reauthorization commitment letter states the draft will publish sometime before the end of 2017.
MORE
September 26, 2016
September 26, 2016
Thrifty White Pharmacy announced Friday that it has received specialty pharmacy accreditation from URAC. "URAC accreditation validates our...
Thrifty White Pharmacy announced Friday that it has received specialty pharmacy accreditation from URAC. "URAC accreditation validates our comprehensive specialty pharmacy program," said Jeremy Faulks, director of specialty pharmacy at Thrifty White.
MORE

Pages